B6(Cg)-Tg(RIP1-Tag)5Dh/Orl
| Status | Available to order |
| EMMA ID | EM:15290 |
| International strain name | B6(Cg)-Tg(RIP1-Tag)5Dh/Orl |
| Alternative name | Tg(RIP1-Tag)5Dh or RIP1-Tag5 (C57BL/6) |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(RIP1-Tag)5Dh |
| Gene/Transgene symbol | Tg(RIP1-Tag)5Dh |
Information from provider
| Provider | Douglas Hanahan |
| Provider affiliation | SV, EPFL/ISREC/Ludwig Lausanne |
| Genetic information | Transgenic (inserted expressed sequence) mouse model. This transgene contains the rat Ins2 (insulin 2) promoter and the wild-type allele of the SV40 large T antigen gene. Expression is driven in pancreatic beta cells leading to pancreatic neuroendocrine cancer. |
| Phenotypic information | Homozygous:NAHeterozygous:Mouse model of pancreatic neuroendocrine tumor (only males are used). Constitutive expression of the transgene (SV40-TAg oncoprotein) in beta cells of the pancreatic islets leading to development of tumors in the pancreas: - Hyperplastic islets begin to appear by 14 weeks of age - Angiogenic islets (8 to 12% of the total) arise from hyperplastic/dysplastic islets by switching on angiogenesis (around 16 weeks of age) - Solid tumors (~3% of the islets) emerge at about 20-25 weeks as small, encapsulated adenomas that progress into large adenomas by 24 weeks Monitoring starts at 20 weeks due to the heterogeneity of the tumor growth. Insulin secreted by adenomas makes the mice hypoglycemic; therefore, glucose level needs to be monitored. - End point is around 30 week-old mice. |
| Breeding history | more than 10 |
| References | None available |
| Homozygous fertile | not known |
| Homozygous viable | not known |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | Institut de Transgenose, INTRAGENE, Orléans, France |
| Animals used for archiving | heterozygous C57BL/6N |